6 key clin­i­cal tri­al trends that we should em­brace and build on

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.

When peni­cillin was dis­cov­ered in 1928 by Alexan­der Flem­ing, the av­er­age clin­i­cal tri­al time was 12 years. In 2021, the av­er­age in­dus­try tri­al time is 10 years, an im­prove­ment of on­ly 2 years. In al­most a cen­tu­ry, there have been no ad­vance­ments that have de­liv­ered a sub­stan­tial change to how clin­i­cal tri­als are con­duct­ed.

While the Covid-19 pan­dem­ic it­self had a dev­as­tat­ing im­pact on tri­als around the world, the dis­rup­tion it caused al­so car­ries with it the chance for in­no­va­tion. The ur­gency and ac­cel­er­a­tion to adopt new ways of work­ing caused by the pan­dem­ic is al­so an op­por­tu­ni­ty. By main­tain­ing the in­no­va­tion mind­set that ini­tial­ly came from ne­ces­si­ty, the in­dus­try can dri­ve durable, sus­tain­able in­no­va­tion with the po­ten­tial to trans­form the clin­i­cal de­vel­op­ment mod­el. Here are 6 key trends that we should em­brace and build on mov­ing for­ward.

The first key trend that should pre­vail is a mind­set of not “just in time,” but “just in case.” By proac­tive­ly think­ing about what might go wrong and build­ing “dis­rup­tion-proof­ing” steps in­to tri­al pro­to­cols from the very start, teams can piv­ot more quick­ly, min­i­miz­ing in­ter­rup­tions for staff, in­ves­ti­ga­tors, and most im­por­tant­ly, peo­ple par­tic­i­pat­ing in the clin­i­cal tri­al.

Sec­ond­ly, the pan­dem­ic forced the in­dus­try to quick­ly move as much of our busi­ness to vir­tu­al as pos­si­ble, with teams con­duct­ing site vis­its and in­ves­ti­ga­tor en­gage­ment re­mote­ly. Even as reg­u­la­tions ease, we are see­ing that sites, in­ves­ti­ga­tors and pa­tients are all em­brac­ing vir­tu­al as the new norm. In­dus­try should fol­low suit and con­tin­ue to in­clude ac­tiv­i­ties such as re­mote mon­i­tor­ing and dig­i­tal pa­tient so­lu­tions in­to tri­als where ap­pro­pri­ate.

Em­brac­ing vir­tu­al so­lu­tions will al­so help sup­port the third key trend – home is the new tri­al site. With many sites be­com­ing Covid treat­ment cen­ters, it be­came both dif­fi­cult and po­ten­tial­ly dan­ger­ous for some clin­i­cal tri­al pa­tients to go to the hos­pi­tal. Im­ple­ment­ing tac­tics around this trend, teams worked to set up so­lu­tions such as in-home nurs­ing pro­grams or di­rect to pa­tient ship­ments of their study med­ica­tion. These are op­tions that pa­tients may pre­fer, re­gard­less of re­stric­tions, and many tri­al sites have now ex­pand­ed their ca­pa­bil­i­ties to ac­com­mo­date these ser­vices. There­fore, we need to pri­or­i­tize build­ing as­sess­ment of de­cen­tral­ized clin­i­cal tri­al el­e­ments, such as home nurs­ing, di­rect to pa­tient drug de­liv­ery or telemed­i­cine op­tions, in­to tri­al pro­to­cols.

That com­mit­ment to pa­tient pref­er­ences leads to the next trend – the rise of the pa­tient as a con­sumer. Dur­ing Covid, in­dus­try and var­i­ous teams worked at an al­most in­di­vid­ual lev­el to en­sure every clin­i­cal tri­al pa­tient had ac­cess to their treat­ment. Why should this end? The needs of each pa­tient are unique and it is up to us as re­searchers to de­vel­op flex­i­ble tri­al en­gage­ment op­tions that re­duce their bur­den. In fact, based on the changes im­ple­ment­ed dur­ing the pan­dem­ic, pa­tients have the right to ex­pect that tri­als can be struc­tured to suit them, ver­sus adapt­ing their life to the tri­al. We be­lieve the so­lu­tions, process­es and tech­nol­o­gy that were put in place dur­ing the pan­dem­ic set a strong foun­da­tion of pa­tient-cen­tric­i­ty that all can con­tin­ue to build up­on.

The key un­der­ly­ing com­po­nent that en­abled teams to lead in the ar­eas above is tech­nol­o­gy. Pri­or to Covid, clin­i­cal tri­als were a large­ly man­u­al op­er­a­tion, re­quir­ing peo­ple to vis­it hos­pi­tals and sites. The sit­u­a­tion man­dat­ed that com­pa­nies em­brace in­no­v­a­tive so­lu­tions, in­clud­ing tech­nolo­gies that en­abled re­mote mon­i­tor­ing and vir­tu­al­iza­tion. Adopt­ing these new tech­nolo­gies en­sured that com­pa­nies and teams could re­main ag­ile and sus­tain en­gage­ment with sites and pa­tients to keep tri­als pro­gress­ing while en­sur­ing tri­al and da­ta in­tegri­ty. There­fore, the fifth key trend is the ev­i­dence that tech­nol­o­gy en­ables re­silience dur­ing dis­rup­tions.

As de­scribed above, the pace of the pan­dem­ic caused phar­ma­ceu­ti­cal com­pa­nies to very quick­ly make de­ci­sions and put so­lu­tions in place. In fact, as an in­dus­try we did not wait for guid­ance and in­stead fo­cused on do­ing what was right for our pa­tients, sites and in­ves­ti­ga­tors. By forg­ing ahead and do­ing what was need­ed, the prac­tices that we put in place were then fol­lowed and for­mal­ized by pol­i­cy. This achieve­ment il­lus­trates the sixth and last key trend: let prac­tice in­form pol­i­cy ver­sus pol­i­cy dic­tat­ing prac­tice. Col­lec­tive­ly, we demon­strat­ed to pol­i­cy mak­ers that we can lead and bring for­ward the right ap­proach­es, shift­ing our role from wait­ing for pol­i­cy to shap­ing pol­i­cy.

For the first time in al­most a cen­tu­ry, we have the op­por­tu­ni­ty to change the clin­i­cal de­vel­op­ment mod­el. While each of these trends has po­ten­tial on its own, by em­brac­ing them to­geth­er we can cre­ate durable and sus­tain­able change. For ex­am­ple, com­pa­nies con­duct­ing tri­als for Covid saw the time it took for each stage of the tri­al – start-up, ex­e­cu­tion and close-out – re­duced by as much as 10-fold. This is proof of what can be achieved. It is up to us to seize this mo­ment where, as an in­dus­try, we can trans­form how clin­i­cal tri­als are con­duct­ed.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.

Volker Wagner (L) and Jeff Legos

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Ten years ago, a small Norwegian biotech by the name of Algeta showed up at ESMO — then the European Multidisciplinary Cancer Conference 2011 — and declared that its Bayer-partnered targeted radionuclide therapy, radium-223 chloride, boosted the overall survival of castration-resistant prostate cancer patients with symptomatic bone metastases.

In a Phase III study dubbed ALSYMPCA, patients who were treated with radium-223 chloride lived a median of 14 months compared to 11.2 months. The FDA would stamp an approval on it based on those data two years later, after Bayer snapped up Algeta and christened the drug Xofigo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.

Ex­elix­is pulls a sur­prise win in thy­roid can­cer just days ahead of fi­nal Cabome­tyx read­out

Exelixis added a thyroid cancer indication to its super-seller Cabometyx’s label on Friday — months before the FDA was expected to make a decision, and days before the company was set to unveil the final data at #ESMO21.

At a median follow-up of 10.1 months, differentiated thyroid cancer patients treated with Cabometyx (cabozantinib) lived a median of 11 months without their disease worsening, compared to just 1.9 months for patients given a placebo, Exelixis said on Monday.

Den­mark's Gubra to col­lab­o­rate with Bay­er on pep­tides; Sam­sung and Bio­gen re­ceive FDA ap­proval for Lu­cen­tis biosim­i­lar

Danish biotech Gubra announced a research collaboration and license agreement with Bayer to develop peptide therapeutics to treat cardiorenal diseases. The collaboration will utilize Gubra’s peptide drug discovery platform to identify potential candidates.

This is not the first time Gubra has partnered with a company on peptide therapeutics — they partnered with Boehringer Ingelheim back in 2017 to create peptide therapeutics to treat obesity.

Ex-My­lan em­ploy­ee pleads guilty to in­sid­er trad­ing, il­le­gal­ly deal­ing on FDA ap­provals, earn­ings and Up­john merg­er

A former Mylan IT executive pleaded guilty Friday to an insider trading scheme where he bought and sold stock options on another executive’s advice.

Prosecutors secured the plea from Dayakar Mallu, Mylan’s former VP of global operations information technology, after uncovering the plan. Mallu collaborated with an unnamed “senior manager,” the SEC said, to trade options ahead of Mylan public announcements regarding FDA approvals, revenue reports and its merger with the Pfizer generics subsidiary Upjohn. The two subsequently shared profits.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.

Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.

Mi­rati tri­umphs again in KRAS-mu­tat­ed lung can­cer with a close­ly watched FDA fil­ing now in the cards

After a busy weekend at #ESMO21, which included a big readout for its KRAS drug adagrasib in colon cancer, Mirati Therapeutics is ready to keep the pressure on competitor Amgen with lung cancer data that will undergird an upcoming filing.

In topline results from a Phase II cohort of its KRYSTAL-1 study, adagrasib posted a response rate of 43% in second-line-or-later patients with metastatic non-small cell lung cancer containing a KRAS-G12C mutation, Mirati said Monday.